Patient Group Leader Workshop

Sign up to attend the Patient Group Leader Workshop hosted by the ARM Foundation for Cell & Gene Medicine on Tuesday, February 25, 2020 from 9:00 a.m. – 11:30 a.m. at the Eaton Hotel in Washington DC. This workshop, for patient organization leaders, will give you a chance to explore resources designed to educate your

Webinar Answers Patient, Family Questions about Cell and Gene Therapy Clinical Trials

WASHINGTON, DC, December 10, 2019 – The ARM Foundation for Cell & Gene Medicine, a leading cell and gene medicine education and research organization, will co-sponsor a live webinar with the Center for Information and Study on Clinical Research Participation (CISCRP) entitled, “Understanding Cell and Gene Therapy Clinical Trials,” at noon ET, December 12, 2019. The

Cigna Health Services Business Pioneers an Innovative Solution to Affordably Bring Life-Changing Therapies to Patients

“Breakthrough, potentially life-changing medicines offer great promise for patients and their families. However, the high prices of the medicines – millions of dollars in some cases – threaten coverage and access by patients who may benefit. “Today, Cigna’s health services business is introducing Embarc Benefit ProtectionSM, a new offering that brings together the health services,

First gene therapy to treat rare blood disease nears European approval

“The first gene therapy to treat a rare blood disorder is one step closer to approval Friday following a recommendation by European officials. “Lentiglobin, the gene therapy for beta-thalassemia developed by Cambridge, Mass.-based Bluebird Bio, was recommended for approval by the Committee for Medicinal Products for Human Use (CHMP), the drug-reviewing arm of the European

CRISPR Drapes Invisibility Cloak over Stem Cells

“An international research team has used CRISPR-Cas9 gene editing to render induced pluripotent stem cells (iPSCs) invisible to the immune system, a bioengineering sleight of hand that initial in vivo tests suggest could open the door to generating stem cells for universal transplantation. The new approach, developed by scientists at the University of California, San

CMS unveils CAR-T proposal, with emphasis on patient outcomes

“Two CAR-T therapies — Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel) — are already on the market, yet their high price tags and potentially one-time administration has put pressure on CMS to figure out a way to cover these kinds of treatments. The agency took a few steps toward that goal over the

REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy

“REGENXBIO announced the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to RGX-181. RGX-181 is a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene. In addition to the Rare

ARM Extends Its Reach

Adding Education to Advocacy at the Alliance for Regenerative Medicine “In the beginning of the new millennium, a new therapeutic approach also dawned — actually a number of new approaches gathered collectively under the umbrella term “regenerative medicine (RM).” The most notable case in the first years of the 2000s concerned Christopher Reeve, the first

Bridging The Public Knowledge Gap Around Cell And Gene Medicine

By: Morrie Ruffin, Executive Director, ARM Foundation for Cell and Gene Medicine in Cell & Gene Cell and gene therapies hold the potential to transform medicine; however, if patients are to gain access to these therapies, we must increase public awareness and understanding of how these therapies can benefit them. According to a review of

ARM Foundation for Cell and Gene Medicine Announces Board of Directors Appointments

Experts in regenerative medicine bring exceptional leadership to ARM Foundation to help increase understanding and acceptance of cell and gene medicine. Washington, D.C., August 14, 2018 – The ARM Foundation for Cell & Gene Medicine (ARM Foundation), an independent 501(c)(3) non-profit organization, today announced five appointments to its Board of Directors: Amy DuRoss of Vineti;

  • 1
  • 2